Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samarium 153 Followed by Salvage Radiotherapy in High-Risk Prostate Cancer
NCT00551525Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Apr 2008
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of samarium-153 lexidronam in prostate cancer (PCa), sponsored by NRG Oncology. Primary endpoint: Proportion of Patients With PSA Response Within 12 Weeks of Samarium 153 Administration. Started Apr 2008; status: completed.
02
Drugs
samarium-153 lexidronam
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00551525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551525.